Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
… P=0.360) were not statistically different.Conclusion Different cangrelor dosing regimens demonstrated no significant differences in thro…
…comes.Results 54 adult patients (n=32 men, n=22 women) received cangrelor intraoperatively. The most common indications were acute ischem…
…ee patients, our experience aligns with adult data and supports cangrelor’s feasibility as an adjunct or bridge in acute pediatric neuroi…
…onset, predictable platelet inhibition, and rapid offset, while eptifibatide (GP IIb/IIIa inhibitor) provides broader platelet inhibition wi…
…day 1 patency, 90-day mortality, or symptomatic ICH.Conclusions Cangrelor showed comparable safety and efficacy to GPIIb/IIIa inhibitors.…
…s due to their slow onset of action and inconsistent responses. Cangrelor, an intravenous P2Y12 inhibitor with rapid action, may provide …
…. Given ongoing thrombosis and suspected complement activation, eculizumab was initiated. The patient stabilized without further thromboti…
… administration, and monitoring considerations are provided for aspirin, clopidogrel, prasugrel, ticagrelor, cangrelor, and glycoprotei…
…y was selected based on drug availability, with eptifibatide or cangrelor being used in most cases.The group was divided into patients wi…
…lized. Due to bilateral PEs, anticoagulation was initiated with heparin and transitioned to cangrelor.Abstract C94 Figure 2Conclusions …